

Future-proof HTA

The need for innovative HTA methods for more complex and personalized medicine

Dr. W. Goettsch, PhD^{1,2}

1.WHO Collaborating Centre for Pharmaceutical Policy, Utrecht University, The Netherlands

2.National Health Care Institute (ZIN), Diemen, The Netherlands

Farmaco-epidemiologie en Klinische Farmacologie




Universiteit Utrecht

New realities?

MM treatment in NL daily practice

MS treatment in NL daily practice



Franken, MG. et al. Policymaker, Please Consider Your Needs Carefully: Does Outcomes Research in Relapsed or Refractory Multiple Myeloma Reduce Policymaker Uncertainty Regarding Value for Money of Bortezomib? Value in Health 2014, Volume 17, Issue 2, 245 - 253 Nederland / ĜIP (2018)

Bron: Zorginstituut Nederland

zorgverzekeraars, verstrekt via

Vektis (2018) en Zorginstituut

o.b.v. declaratiedata van

2014-2016



Universiteit Utrecht

Farmaco-epidemiologie en Klinische Farmacologie

Changing HTA paradigms (future-proof HTA?)

- Personalized treatments
 - Smaller populations
 - Combinations of treatments, different sequences
 - Companion diagnostics (genetic testing)
- Real world evidence (RWE)
- Internationalization
 - Clinical assessments on an European level for single technologies (pharma and medtech)



on health technology assessment and amending Directive 2011/24/EI

Universiteit Utrecht

Farmaco-epidemiologie en Klinische Farmacologie







About the HTx project

- Horizon 2020 project supported by the European Union, kickingoff in January 2019 and lasting for 5 years.
- Facilitate the development of methodologies to deliver more customized information on the effectiveness and costeffectiveness of complex and personalised combinations of health technologies.
- Provide methods to support personalised treatment advice that will be shared with patients and their physicians.
- In close collaboration with the European Network for HTA (EUnetHTA) and its stakeholders pilot the implementation of these methods in Europe.



© The HTx Consortium 2019-2023. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N⁰ 825162.




HTx – Participants

- Utrecht University (project coordinator) (UU) Netherlands
- University of Copenhagen (UoC), Denmark
- University of Oulu (UoO) Finland
- University of York (UoY) UK
- Medical University of Sofia (MUS) Bulgaria
- University of Bern (UBERN)
 Switzerland
- Universidad Politecnia de Madrid (UPM) Spain
- European Organisation for
 Research and Treatment of Cancer
 The HTx Consortium 2019-2023. This project has received funding from
 EORt fgC) at Berggi (research and innovation programme

- Dental and Pharmaceutical Benefits Agency (TLV) Sweden
- National Health Care Institute (ZIN) Netherlands
- National Institute of Health and Care Excellence (NICE) UK
- Syreon Research Institute (SRI) Hungary
- Synapse research management (SYNAPSE) Spain
- EURORDIS Rare Diseases Europe (EURORDIS) France
- University of Maastricht (UM) Netherlands


Interventions





 $\ensuremath{\mathbb{C}}$ The HTx Consortium 2019-2023. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement Nº 825162.

Concepts





 \circledcirc The HTx Consortium 2019-2023. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement Nº 825162.





- Prediction modelling on the basis of data using different study designs (RCT, RWD etc) (WP2)
- Health-econometric tools to take into account effects and costs (WP2)
- Develop AI/ML methods to forecast individual patient treatment outcomes (WP3)

Focus on combinations (and/or sequences) of health technologies not evaluated in RCT as such

WP1



Case studies



- Proton therapy for head and neck cancer
- Monitoring and treatment pathways in diabetes (T1DM and T2DM)
- Pharmacological treatments for relapsing multiple sclerosis (MS)
- Different treatment modalities in patients with myelodysplastic syndrome (MDS)

Including framework to generalize results to other indications and settings



Implementation and transferability



- Developing PROMS that are fit for purpose
- Link to flexible funding and reimbursement models
- International consensus on RWD and resulting HTx models between HTA, regulators and guideline developers
- Transferability of case study findings and methods across participating countries
- Develop and disseminate training materials to patients

WP1



How can success of HTx be measured?



- Clear methods developed for certain disease area's;
- Are practically used in healthcare practice
 - By HTA organisations to facilitate HTA for personalised treatments (including support appropriate use);
 - By healthcare providers as part of new guidelines
 - For individual patients and their clinicians
- Provides a general framework that can help other groups to develop methods for specific disease areas
- Has a clear link to national reimbursement and pricing processes.

